285 related articles for article (PubMed ID: 29455416)
1. Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis.
Marino S; Bishop RT; Mollat P; Idris AI
Calcif Tissue Int; 2018 Aug; 103(2):206-216. PubMed ID: 29455416
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological evidence for the bone-autonomous contribution of the NFκB/β-catenin axis to breast cancer related osteolysis.
Marino S; Bishop RT; Logan JG; Mollat P; Idris AI
Cancer Lett; 2017 Dec; 410():180-190. PubMed ID: 28965856
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological Inhibition of NFκB Reduces Prostate Cancer Related Osteoclastogenesis In Vitro and Osteolysis Ex Vivo.
Marino S; Bishop RT; Carrasco G; Logan JG; Li B; Idris AI
Calcif Tissue Int; 2019 Aug; 105(2):193-204. PubMed ID: 30929064
[TBL] [Abstract][Full Text] [Related]
4. Bone Cell-autonomous Contribution of Type 2 Cannabinoid Receptor to Breast Cancer-induced Osteolysis.
Sophocleous A; Marino S; Logan JG; Mollat P; Ralston SH; Idris AI
J Biol Chem; 2015 Sep; 290(36):22049-60. PubMed ID: 26195631
[TBL] [Abstract][Full Text] [Related]
5. Hydrogen sulphide-releasing diclofenac derivatives inhibit breast cancer-induced osteoclastogenesis in vitro and prevent osteolysis ex vivo.
Frantzias J; Logan JG; Mollat P; Sparatore A; Del Soldato P; Ralston SH; Idris AI
Br J Pharmacol; 2012 Mar; 165(6):1914-1925. PubMed ID: 21955294
[TBL] [Abstract][Full Text] [Related]
6. Gold clusters prevent breast cancer bone metastasis by suppressing tumor-induced osteoclastogenesis.
Zhang Z; Yao Y; Yuan Q; Lu C; Zhang X; Yuan J; Hou K; Zhang C; Du Z; Gao X; Chen X
Theranostics; 2020; 10(9):4042-4055. PubMed ID: 32226538
[No Abstract] [Full Text] [Related]
7. TRAF2 in osteotropic breast cancer cells enhances skeletal tumour growth and promotes osteolysis.
Peramuhendige P; Marino S; Bishop RT; de Ridder D; Khogeer A; Baldini I; Capulli M; Rucci N; Idris AI
Sci Rep; 2018 Jan; 8(1):39. PubMed ID: 29311633
[TBL] [Abstract][Full Text] [Related]
8. Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.
Logan JG; Sophocleous A; Marino S; Muir M; Brunton VG; Idris AI
J Bone Miner Res; 2013 May; 28(5):1229-42. PubMed ID: 23239200
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological inhibition of the IKKε/TBK-1 axis potentiates the anti-tumour and anti-metastatic effects of Docetaxel in mouse models of breast cancer.
Bishop RT; Marino S; de Ridder D; Allen RJ; Lefley DV; Sims AH; Wang N; Ottewell PD; Idris AI
Cancer Lett; 2019 May; 450():76-87. PubMed ID: 30790681
[TBL] [Abstract][Full Text] [Related]
10. Oroxylin A suppresses breast cancer-induced osteoclastogenesis and osteolysis as a natural RON inhibitor.
Chen Y; Zheng J; Mo L; Chen F; Li R; Wang Y; Liang Q; Chen Z; Dai W; Chen L; Yan P; Zhou H; Li X
Phytomedicine; 2024 Jul; 129():155688. PubMed ID: 38728920
[TBL] [Abstract][Full Text] [Related]
11. Tumor-supportive and osteoclastogenic changes induced by breast cancer-derived factors are reversed by inhibition of {gamma}-secretase.
Fong JE; Le Nihouannen D; Komarova SV
J Biol Chem; 2010 Oct; 285(41):31427-34. PubMed ID: 20679341
[TBL] [Abstract][Full Text] [Related]
12. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
13. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
Wilson TJ; Nannuru KC; Futakuchi M; Sadanandam A; Singh RK
Cancer Res; 2008 Jul; 68(14):5803-11. PubMed ID: 18632634
[TBL] [Abstract][Full Text] [Related]
14. Combined administration of a small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis.
Bishop RT; Marino S; Carrasco G; Li B; Allen RJ; Sparatore A; Ottewell PD; Mollat P; Sims AH; Capulli M; Wang N; Idris AI
Cancer Lett; 2020 Sep; 488():27-39. PubMed ID: 32474152
[TBL] [Abstract][Full Text] [Related]
15. Human breast cancer induces osteoclast activation and increases the number of osteoclasts at sites of tumor osteolysis.
Clohisy DR; Palkert D; Ramnaraine ML; Pekurovsky I; Oursler MJ
J Orthop Res; 1996 May; 14(3):396-402. PubMed ID: 8676252
[TBL] [Abstract][Full Text] [Related]
16. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases.
Strazic-Geljic I; Guberovic I; Didak B; Schmid-Antomarchi H; Schmid-Alliana A; Boukhechba F; Bouler JM; Scimeca JC; Verron E
Biochem Pharmacol; 2016 Sep; 116():11-21. PubMed ID: 27378505
[TBL] [Abstract][Full Text] [Related]
17. IKKbeta activation is sufficient for RANK-independent osteoclast differentiation and osteolysis.
Otero JE; Dai S; Alhawagri MA; Darwech I; Abu-Amer Y
J Bone Miner Res; 2010 Jun; 25(6):1282-94. PubMed ID: 20200955
[TBL] [Abstract][Full Text] [Related]
18. Regulation of breast cancer induced bone disease by cancer-specific IKKβ.
Marino S; Bishop RT; Capulli M; Sophocleous A; Logan JG; Mollat P; Mognetti B; Ventura L; Sims AH; Rucci N; Ralston SH; Idris AI
Oncotarget; 2018 Mar; 9(22):16134-16148. PubMed ID: 29662632
[TBL] [Abstract][Full Text] [Related]
19. Trolox inhibits osteolytic bone metastasis of breast cancer through both PGE2-dependent and independent mechanisms.
Lee JH; Kim B; Jin WJ; Kim JW; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2014 Sep; 91(1):51-60. PubMed ID: 24929117
[TBL] [Abstract][Full Text] [Related]
20. Artemisinin inhibits breast cancer-induced osteolysis by inhibiting osteoclast formation and breast cancer cell proliferation.
Li J; Feng W; Lu H; Wei Y; Ma S; Wei L; Liu Q; Zhao J; Wei Q; Yao J
J Cell Physiol; 2019 Aug; 234(8):12663-12675. PubMed ID: 30536376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
